《藥學(xué)進(jìn)展》2012年第36卷關(guān)鍵詞(英文)索引

A

AB103 36(12):572

Abraxane 36(11):526

ABT－072 36(5):239

ABT－450 36(5):239

acadesine 36(4):190

acetylcholinesterase inhibitor 36(9):385

action mechanism 36(6):251

activity 36(4):145

Adcetris 36(10):470

additive drug 36(2):83

adverse reaction 36(5):224

adverse drug reaction 36(12):546

ADXS－HPV 36(11):525

Afinitor 36(8):383

agomelatine 36(4):157

alemtuzumab 36(5):237

alert structure 36(1):1

aliskiren 36(5):封3

amino－functionalization 36(9):400

aminothiols 36(4):163

analgesia 36(5):224

androgen receptor antagonist 36(6):251

Anplag?36(11):511

antibacterial activity 36(10):433;(11):481

antibacterial drug 36(4):173

antibacterialmechanism 36(2):49

anti－HIV drug 36(12):539

anti－inflammation 36(10):465

antioxidation 36(4):158

anti－radiation activity 36(4):163

antitumor 36(11):494

antitumor activity 36(2):65;(7):289

antitumor drug 36(7):300

antitumormetastasis 36(1):22

antiviral activity 36(9):394

antiviral drug 36(7):300

apoptosis 36(10):445

application analysis 36(11):514

apricoxib 36(4):186

AR－13324 36(11):525

arrhythmias 36(7):308

articaine 36(5):224

asymmetric oxidation 36(7):325

ATX－101 36(5):237;(12):573

Aurora kinase 36(4):145

avanafil 36(3):135

avastin 36(12):572

B

bacterial resistance 36(11):481

baicalin 36(8):373

betaine 36(8):370

bevacizumab 36(5):封3

bio－activity 36(6):241

bioavailability 36(7):300;(8):347

biological activity 36(10):452

biological therapy 36(5):207

bosutinib 36(9):附頁(yè)2

bretuximab vedotin 36(5):240

brown adipose tissue 36(11):487

Budeprion XL 36(10):451

C

calcium regulatory protein 36(7):308

canagliflozin 36(2):92

capillary gas chromatography 36(11):508

carbon nanotube 36(9):400

carfilzomib 36(8):383;(11):519

carvedilol 36(9):418

castration－resistant prostate cancer 36(6):251

cell adhesionmolecule 36(4):158

cenicriviroc 36(2):93

centrifugal granulation 36(6):264

chalcone 36(6):241

chemicalmodification 36(9):394

chewing gum 36(12):552

chiral separation 36(1):34

chromatographic method 36(6):257

cis/transisomer 36(6):257

clindamycin phosphate 36(11):501

clinical application 36(1):22

cobicistat 36(8):378

combined use 36(4):173

compound glycyrrhizin 36(10):465

concentration polarization 36(3):116

content 36(12):564

content determination 36(1):38;(2):79

controlled－release preparation 36(9):406

correlation 36(8):356

CP－4126 36(9):423

CR845 36(6):285

cryopelletization 36(8):362

CT－1578 36(11):527

CTP－499 36(11):527

cubic liquid crystal 36(1):14

cyclinD1 36(2):73

cyclin dependent kinase 4 36(2):73

β－cyclodextrin inclusion complex 36(12):552

CYD－TDV 36(10):479

cytoprotection 36(10):445

D

delamanid 36(8):380

dexpramipexole 36(1):37

diabetic nephropathy 36(5):193

diacylglycerol acyltransferase inhibitor 36(2):57

dipeptidyl peptidase－4 inhibitor 36(8):337

disease 36(5):199

dissolution 36(9):418

distribution 36(10):452

dosage 36(6):277

dose－effect curve 36(4):180

drotrecoginα 36(4):157

drug 36(5):199

drug carrier 36(7):315;(9):400;(10):459

drug delivery system 36(1):14

drug design 36(1):1

druggability 36(4):151

drug resistance 36(2):49

drug response 36(8):356

drug synthesis 36(5):227

Dulera 36(4):封3

E

EC5036(4):180

eltrombopag 36(12):574

endoplasmic reticulum stress 36(3):104;(5):193;(10):445

endothelial system 36(5):193

endothelin 36(3):104

endothelin－NADPH oxidase pathway 36(7):308

ENMD－2076 36(4):185

enzalutamide 36(10):480;(11):521

enzyme－responsive 36(10):458

EpanovaTM36(5):239

EPI－743 36(10):479

Erivedge 36(2):封3

erythromycin 36(2):49;(11):481

etoposide 36(11):494

EVP－6124 36(11):524

EXPAREL?36(12):576

experimentmodel 36(12):546

extracellular signal－regulated kinase 1/2 36(2):73

extrusion spheronization 36(8):362

F

ferrous sulfate tablet 36(7):321

FICI 36(4):173

flame atomic absorption spectrophotometry 36(1):38

fluorescence technique 36(1):28

formula 36(12):564

formulation 36(9):406

fosinoprilat 36(3):123

fosinopril sodium tablet 36(2):79;(3):123

freeze pelletization 36(8):362

furoxan 36(3):97

G

gastrointestinal toxicity 36(3):110

gene vector

geniposide 36(4):158

genotoxicity 36(3):110

genotype 36(8):356

geographic information system 36(2):87

GKT137831 36(11):524

GLPG0634 36(4):192

glucarpidase 36(7):328

glycididazole sodium 36(11):508

golimumab 36(6):286

GraphPad Prism 5.0?36(4):180

GRPR 36(2):封3

gutmicrobiota 36(5):199

H

halloysite 36(7):315

HCV 36(9):394

heart failure 36(7):308

hepatotoxicity 36(3):110

hexagonal liquid crystal 36(1):14

highly active antiretroviral therapy 36(12):539

high performance capillary electrophoresis 36(1):34

high－throughput screening 36(1):28

HIV 36(5):231;(9):394;(11):526

HIV－1 36(1):46

H2N2 36(12):575

H5N1 36(2):封3;(12):575

hotmelt extrusion 36(8):362

HPLC 36(8):373

HPLC－ELSDmethod 36(8):370

HPLCmethod 36(2):79

huB4－DM4 36(8):377

hydrogel 36(11):501

hydrophilic matrice 36(5):216

4 －h(huán)ydroxy－1－butanesulfonic acid 36(3):128

hypertension 36(12):529

hypoxia－activated prodrug 36(2):65

hypoxic selectivity 36(2):65

I

iCALM 36(7):320

idiosyncratic liver injury 36(12):546

idiosyncratic drug toxicity 36(1):1

imipenem and cilastatin sodium 36(6):277

immune therapy 36(5):207

individualized treatment 36(8):356

inflammatory cytokine 36(3):104

inflammatory factor 36(10):465;(11):511

influenza virus 36(9):394

influncing factor 36(5):216

inhibitor 36(4):145

inhibitory activity 36(9):385

insoluble particles 36(2):83

insulin resistance 36(6):270

interaction 36(5):199

intravenous infusion 36(2):83

invitrorelease 36(11):501

iodine 36(12):552

ion chromatography 36(3):128

ISIS－STAT3(Rx)36(11):518

ivacaftor 36(3):144

K

kidney damage 36(10):445

KW－3357 36(3):142

Kyprolis 36(8):383

L

lansoprazole 36(7):325

Latuda 36(5):238

Lazanda 36(3):144

LC－MS/MS 36(3):123;(9):413

lesinurad 36(7):331

levornidazole 36(6):277

lidocaine 36(5):224

linaclotide 36(9):附頁(yè)1

lipopolysaccharide 36(10):465

Lipoquin 36(12):576

lixisenatide 36(3):132

local anesthesia 36(5):224

low－temperature vacuum drying 36(10):471

LuAA21004 36(5):238

luteolin 36(4):173

Lycii Fructus 36(8):370

M

macitentan 36(5):240

macrolide 36(2):49

male hypogonadism 36(3):104

malignant lymphoma 36(5):207

mambalgins 36(10):480

Marqibo 36(8):384

MDV－3100 36(3):131

medicine selling system 36(2):87

melanin 36(4):158

membrane filtration method 36(12):559

membrane fouling 36(3):116

membrane selectivity 36(3):116

metabolic activation 36(1):1

metal complex 36(4):163

method validation 36(12):559

MetMAb 36(7):330

MIC 36(4):173

micronomicin sulfate injection 36(12):559

mifepristone 36(6):270

mirabegron 36(3):133

molding technique 36(10):471

monoclonal antibody 36(5):207

monolithic osmotic pump 36(9):406

Mosquirix 36(3):136

moxifloxacin 36(6):277

MRSA 36(4):173

N

NanoTab 36(12):571

nanotube 36(7):315

natural benzophenones 36(10):452

natural product 36(9):385

near－infrared spectroscopy 36(7):321

Negishi coupling reaction 36(5):227

nephrotoxicity 36(3):110

new target 36(12):539

NF－κB/IκB pathway 36(4):158

nitric oxide 36(3):97

nitric oxide－donating drug 36(3):97

nonpeptide renin inhibitor 36(12):529

nucleoside drug 36(7):300

Nucynta ER 36(9):399

NVC－422 36(5):232

O

obesity 36(2):57;(11):487

obinutuzumab 36(5):233

occurrencemechanism 36(12):546

ocriplasmin 36(12):570

omacetaxinemepesuccinate 36(12):569

onartuzumab 36(7):330

ON 01910.Na 36(1):44

OPC－67683 36(8):380

oral administration 36(8):347

oral hypoglycemic agent 36(11):514

organic solvent residue 36(11):508

orthogonal experimental design 36(12):552

orthogonal test 36(10):471

oxidative stress 36(3):104;(5):193

oxybutynin 36(1):34

P

palonosetron hydrochloride injection 36(12):564

pasireotide 36(5):236

patent protection 36(4):151

peginesatide 36(11):520

pellet 36(6):264;(8):362

PGC－1α 36(11):487

pharmaceutical salt 36(4):151

pharmacokinetic parameter 36(3):123

pharmacokinetic profile 36(4):145

pharmacological action 36(4):158

pharmacological activity 36(3):97

phase transition 36(1):14

phosphorylation 36(2):73

photo－responsive 36(10):458

pH－responsive 36(10):458

pill－airing process 36(10):471

Plac8 36(11):487

plasma concentration 36(3):123;(9):413

platelet aggregation 36(11):511

podophyllotoxin 36(11):494

polypropylene 36(2):83

polyurethane 36(11):501

polyvinyl chloride 36(2):83

ponatinib 36(10):475

poorly soluble drug 36(9):406

PRDM16 36(11):487

preparation method 36(9):400

Primacaine Adrenaline 36(5):224

process parameter 36(6):264

prodrug 36(7):300;(8):347

protein separation and purification 36(3):116

protein tyrosine kinase inhibitor 36(1):28

p66shcgene 36(5):193

PSN821 36(11):封3

PSN842 36(11):封3

push－pull osmotic pump 36(9):406

PV－10 36(11):528

PVPVA64 36(9):418

Q

Qing-Re-Jiang-TangGranules 36(8):373

Qnasl 36(9):封3

Qnexa 36(4):183

Qsymia 36(9):附頁(yè)1

qualitative analysis 36(7):321

quality control 36(12):564

quality standard 36(8):373

quinolone 36(10):433

R

radioprotective agent 36(4):163

ranibizumab 36(11):522

rapid identification 36(7):321

RAW264.7 cell 36(10):465

RDEA－594 36(7):331

redox－responsive 36(10):458

regorafenib 36(4):184

related substance 36(12):564

related substance A 36(2):79

release rate 36(5):216

renin 36(12):529

reproductive toxicity 36(3):110

resistance 36(12):539

resistant mutant prevention concentration 36(6):277

rⅧFc 36(11):523

ribavirin 36(9):413

rigosertib 36(1):44

rindopepimut 36(12):573

RNA interference 36(2):73

ryanodine receptor 2 36(7):308

S

salt form 36(4):151

sandwiched osmotic pump 36(9):406

saponins 36(3):110

SAR3419 36(8):377

sarpogrelate hydrochloride 36(11):511

Sativex 36(4):封3

SB－509 36(9):424

secukinumab 36(9):425

selectivity 36(4):145

selumetinib 36(12):568

side effect 36(8):347

signal transducer and activator of transcription 3 36(7):289

single enantiomer 36(7):325

smart nanomaterials 36(10):458

SMYD3gene 36(2):73

sofosbuvir 36(12):563

solid dispersion 36(9):418

solithromycin 36(2):94

solubility 36(9):418

spectroscopic method 36(6):257

spherical agglomerate 36(8):362

STAT3 36(11):518

Steovess 36(10):480

sterility test 36(12):559

Stribild 36(9):附頁(yè)1

strontium ranelate suspension 36(1):38

structural feature 36(10):452

structuralmodification 36(6):241;(10):433;(11):494

structure－activity relationship 36(2):49;(4):163;(6):241; (7):289;(8):337;(9):394; (10):433;(11):494

structuremodification 36(11):481

structure optimization 36(4):145

sufentanil 36(12):571

sulfated－β－cyclodextrin 36(1):34

sulfobutyl ether－β－cyclodextrin 36(3):128

sustained release 36(7):315

sustained release effect 36(8):347

sustained release formulation 36(5):216

synergestic effect 36(4):173

Synribo 36(12):569

synthesis 36(10):433

T

tafacitinib 36(5):235

TAK－875 36(1):43

targeted therapy 36(5):207

teduglutide 36(6):285

teriflunomide 36(3):143

testicular lesion 36(3):104

TG－101348 36(10):476

TH－302 36(10):477

thermo－responsive 36(10):458

thiaheterocycles 36(4):163

4 －thiazolidone 36(9):394

thin layer chromatography 36(8):373

thoracic aortic 36(6):270

time－kill curve 36(4):173

tinidazole 36(6):277

TNF－α 36(6):286

toxicity risk 36(1):1

toxicokinetic parameter 36(9):413

traditional Chinesemedicine 36(1):22

transient ischemic attack 36(11):511

trastuzumab emtansine 36(6):284

triglyceride 36(2):57

Truvada 36(9):附頁(yè)2

Tudorza Pressair 36(8):355

tumor vaccine 36(5):207

type 2 diabetes 36(8):337

type 2 diabetesmellitus 36(2):57

U

ultrafiltration technique 36(3):116

ultraviolet－visible spectrophotometry 36(12):552

unfolded protein response 36(10):445

using frequency 36(11):514

V

vaginal pessary 36(11):501

valsartan 36(5):227

vasoconstriction 36(6):270

VEGF－A 36(9):424

veltuzumab 36(4):188

vismodegib 36(2):封3

VivaGel?36(12):574

volitinib 36(11):封3

Voraxaze 36(7):328

W

water－solubility 36(4):145

Web service 36(2):87

Y

Yuan-Hu-Zhi-Tongdropping pill 36(10):471

Z

Zaltrap 36(8):384

ziv－aflibercept 36(8):384